RxBio’s mission is to discover and develop novel and proprietary medications for the benefit of humankind.
Our Technology Platform
News & Milestones
Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100
Diarrheal disease is a severe health problem with an estimated 1.5 million deaths per year and is the second leading cause of death in children under the age of 5.
A critical barrier in treating diarrheal disease is the lack of easy-to-use effective treatments that target the core mechanism responsible for fluid secretion into the gut lumen.
RxBio's goal is to develop a safe, effective, and easy-to-use treatment for secretory diarrhea that targets the cause of the disease rather than treats its symptoms.CLICK HERE to read more.
The company's primary focus is the discovery and development of novel and proprietary compounds for use in the mitigation of acute radiation syndrome (ARS) – including gastrointestinal acute radiation syndrome (GI-ARS) as well as hematological radiation syndrome (HEM-ARS).
GI-ARS occurs as a result of unintended exposure to lethal doses of ionizing radiation (i.e. nuclear-weapon detonation, during manufacture and development of nuclear energy materials, following nuclear accidents, etc.). Government estimates are that many thousands would likely be at risk of developing ARS following detonation of an improvised nuclear device. Treating GI-ARS is the current limiting step in survival. There is no current therapy for this devastating and life-threatening condition. Read More